News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Maxim Group. They set a "buy" rating and a $17.00 price target on the stock.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

Nuvectis Pharma, Inc. (NASDAQ: NVCT) is now covered by analysts at Laidlaw. They set a "buy" rating and a $19.00 price target on the stock.

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

5/7/2024

08:00 am

nvct

-7.3%

BEAT

Form 10-K Nuvectis Pharma, Inc. For: Dec 31

Form 8-K Nuvectis Pharma, Inc. For: Feb 25

Form 4 Nuvectis Pharma, Inc. For: Feb 07 Filed by: Mosseri Marlio Charles

Form 424B5 Nuvectis Pharma, Inc.

Form 8-K Nuvectis Pharma, Inc. For: Feb 05

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}